Plain-English translation of NCT06541704 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing two experimental medications called and for people with geographic atrophy, a serious form of age-related macular degeneration that affects your central vision. Some participants will receive both medications together, some will receive alone, and some will receive a placebo (a non-active treatment). The study will measure whether these treatments can slow or stop the worsening of vision loss.
Geographic atrophy is an advanced stage of age-related macular degeneration with no proven treatments yet. This trial is exploring whether this medication can help slow the progression of vision loss that currently has very limited treatment options.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to one of three groups: one receiving both medications by injection, one receiving one medication by injection alone, or one receiving a placebo. You will visit the clinic regularly so doctors can monitor your vision, examine your eyes, take images of the back of your eye, and draw blood to check how the medication is working and if there are any side effects. The study will track whether your vision stays stable or improves compared to those on placebo.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States